Search research articles
Contact Us
Filters
Showing results (71-80 of 79) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 79 results.
Vox Sanguinis
|
September 2, 2000
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies
C P Engelfriet, H W Reesink, P M Mannucci, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2012
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
J Schwarz, J Astermark, E D Menius, et al.
British Journal of Haematology
|
September 1, 1996
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups
D Menache, D L Aronson, F Darr, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2004
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
M D Tarantino, P W Collins, C R M Hay, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 5, 2016
Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System
R Kulkarni, R J Presley, J M Lusher, et al.
Thrombosis and Haemostasis
|
December 30, 1998
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
N S Key, L M Aledort, D Beardsley, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2004
Consensus recommendations for use of central venous access devices in haemophilia
B M Ewenstein, L A Valentino, J M Journeycake, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 9, 2014
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels
A D Shapiro, M V Ragni, R Kulkarni, et al.
Blood Advances
|
November 24, 2020
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development
B M Reipert, B Gangadharan, C J Hofbauer, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 79) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 79 results.
Vox Sanguinis
|
September 2, 2000
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies
C P Engelfriet, H W Reesink, P M Mannucci, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2012
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
J Schwarz, J Astermark, E D Menius, et al.
British Journal of Haematology
|
September 1, 1996
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups
D Menache, D L Aronson, F Darr, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2004
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
M D Tarantino, P W Collins, C R M Hay, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 5, 2016
Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System
R Kulkarni, R J Presley, J M Lusher, et al.
Thrombosis and Haemostasis
|
December 30, 1998
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
N S Key, L M Aledort, D Beardsley, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2004
Consensus recommendations for use of central venous access devices in haemophilia
B M Ewenstein, L A Valentino, J M Journeycake, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 9, 2014
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels
A D Shapiro, M V Ragni, R Kulkarni, et al.
Blood Advances
|
November 24, 2020
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development
B M Reipert, B Gangadharan, C J Hofbauer, et al.
Page
of 8